Session Information
AABB Annual Meeting & CTTXPO 2011
Click here to go to the previous page
Late-Breaking Information on the Role of Leukocyte Antibodies in TRALI
Track : TC - Technical/Clinical
Program Code: 9210-TC
Date: Sunday, October 23, 2011
Time: 10:30 AM to 12:00 PM  PST
Location: Ballroom 20BC
DIRECTOR :
Brian Curtis, PhD, D(ABMLI), MT(ASCP)SBB, Director, Platelet & Neutrophil Immunology lab, BloodCenter of Wisconsin
MODERATOR :
Brian Curtis, PhD, D(ABMLI), MT(ASCP)SBB, Director, Platelet & Neutrophil Immunology lab, BloodCenter of Wisconsin
SPEAKER (S):
Brian Curtis, PhD, D(ABMLI), MT(ASCP)SBB, Director, Platelet & Neutrophil Immunology lab, BloodCenter of Wisconsin
The Molecular Basis of HNA-3 and its Importance in TRALI,,
Patricia Kopko, MD, Clinical Professor of Pathology, University of California, San Diego
The Role of HLA Class II in TRALI
Christopher Silliman, MD, PhD, FAAP, Senior Independent Investigator/Professor (tenured), Bonfils Blood Center/Univ of CO at Denver Sch Med
In vivo and in vitro modeling of TRALI Pathophysiology
Description
Transfusion-related acute lung injury (TRALI) continues to be the leading cause of transfusion-related death, and therefore, an important issue for the blood bank and transfusion medicine communities. Three lectures will be presented reviewing recent research findings made concerning HNA-3a antibodies, class I and II HLA antibodies, and bioactive lipids in TRALI. The first speaker will review findings that choline transporter-like protein 2 (CTL2) is the protein carrier of HNA-3a/3b, the HNA-3a/3b genetic polymorphism, and recent work to develop a blood donor screening assay for HNA-3 antibodies. The second speaker will describe data on the frequency of HLA class II antibodies in TRALI and recent studies on the mechanism for HLA class II antibodies in TRALI. The third speaker will describe findings made with recent rat model studies and how this data has advanced our understanding of the mechanisms responsible for TRALI caused by HLA class I antibodies and bioactive lipids.






This session offers Self-Assessment Module (SAM) credit. Please complete the post test to receive SAM credit.

  • Describe the role of HLA class II antibodies in causing TRALI and the mechanism involving monocyte activation.
  • Discuss the utility of a recent rat model of TRALI in helping to unravel the pathophysiologic mechanism of TRALI caused by class I HLA antibodies and bioactive lipids.
  • Name and describe the protein carrier of the human neutrophil antigens (HNA)-3a/3b, and describe work to develop a blood donor screening assay for HNA-3a and -3b antibodies.


CE CategoryCE Value
California Clinical Laboratory Personnel 1.5
California Nurse 1.8
Florida Laboratory Personnel 1.8
General Attendee 1.5
Physician 1.5
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.


Handout Online
(Code: 9210-TC)
List Price:Free
  
This session is a part of:
Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are
the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text
are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or
reproduction of any materials herein is strictly prohibited.